Review



primary antibodies against arid1a  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    Cell Signaling Technology Inc primary antibodies against arid1a
    Primary Antibodies Against Arid1a, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary+antibodies+against+arid1a/arid1a+antibody/pm38100120-43-15-18
    Average 90 stars, based on 1 article reviews
    primary antibodies against arid1a - by Bioz Stars, 2026-11
    90/100 stars

    Images

    Related Articles

    Incubation:

    Article Title: ARID1A loss induces P4HB to activate fibroblasts to support lung cancer cell growth, invasion, and chemoresistance
    Article Snippet: .. Membranes were blocked in 5% fat‐free milk and incubated overnight at 4°C with primary antibodies against ARID1A (Cell Signaling Technology), P4HB (Abcam), nonphospho (active) β‐catenin (Cell Signaling Technology), β‐catenin (Cell Signaling Technology), and GAPDH (Cell Signaling Technology). .. After washing, the membranes were incubated with appropriate horseradish peroxidase (HRP)‐conjugated secondary antibodies (Cell Signaling Technology).

    Article Title: ARID1A loss induces P4HB to activate fibroblasts to support lung cancer cell growth, invasion, and chemoresistance.
    Article Snippet: .. Membranes were blocked in 5% fat- free milk and incubated overnight at 4°C with primary antibodies against ARID1A (Cell Signaling Technology), P4HB (Abcam), nonphospho (active) β- catenin (Cell Signaling Technology), β- catenin (Cell Signaling Technology), and GAPDH (Cell Signaling Technology). .. After washing, the membranes were incubated with appropriate horseradish peroxidase (HRP)conjugated secondary antibodies (Cell Signaling Technology).



    Similar Products

    90
    Cell Signaling Technology Inc primary antibodies against arid1a
    Primary Antibodies Against Arid1a, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary+antibodies+against+arid1a/arid1a+antibody/pm38100120-43-15-18
    Average 90 stars, based on 1 article reviews
    primary antibodies against arid1a - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    94
    ABclonal Biotechnology primary antibodies against arid1a
    Primary Antibodies Against Arid1a, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary+antibodies+against+arid1a/BAF250+Rabbit+pAb/pm37142816-67-5-13
    Average 94 stars, based on 1 article reviews
    primary antibodies against arid1a - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    90
    Millipore primary antibodies against arid1a
    Drugs that exhibited significantly lower IC 50 values in <t> ARID1A </t> -mutant cancer cell lines than in ARDI1A -wildtype cancer cell lines
    Primary Antibodies Against Arid1a, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary+antibodies+against+arid1a/arid1a+antibody/pmc05302963-143-14-17
    Average 90 stars, based on 1 article reviews
    primary antibodies against arid1a - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    94
    Santa Cruz Biotechnology mouse monoclonal primary antibody against baf250a
    Patient characteristics according to the expression of <t> BAF250a. </t>
    Mouse Monoclonal Primary Antibody Against Baf250a, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary+antibodies+against+arid1a/ARID1A+Antibody/pmc05038207-84-8-19
    Average 94 stars, based on 1 article reviews
    mouse monoclonal primary antibody against baf250a - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    Image Search Results


    Drugs that exhibited significantly lower IC 50 values in  ARID1A  -mutant cancer cell lines than in ARDI1A -wildtype cancer cell lines

    Journal: Oncotarget

    Article Title: Loss of ARID1A expression leads to sensitivity to ROS-inducing agent elesclomol in gynecologic cancer cells

    doi: 10.18632/oncotarget.10921

    Figure Lengend Snippet: Drugs that exhibited significantly lower IC 50 values in ARID1A -mutant cancer cell lines than in ARDI1A -wildtype cancer cell lines

    Article Snippet: After transferring the protein to a nitrocellulose membrane, the membrane was incubated with primary antibodies against ARID1A (Sigma-Aldrich), BRG1 (Cell Signaling Technology, Danvers, MA, USA), SNF5 (Cell Signaling Technology), and vinculin (Cell Signaling Technology).

    Techniques: Mutagenesis

    a. Western blot analysis of ARID1A protein expression in a panel of 14 endometrial and ovarian cancer cell lines. b. Cell growth of endometrial and ovarian cancer cell lines treated with elesclomol for 72 h as measured using the WST-1 assay. Cell growth was quantified relative to DMSO treated controls. c. IC 50 values of elesclomol in the cell lines in b. d. Apoptosis of ARID1A -mutant and ARID1A -wildtype cells treated with elesclomol for 72 h as measured using annexin-V and PI staining.

    Journal: Oncotarget

    Article Title: Loss of ARID1A expression leads to sensitivity to ROS-inducing agent elesclomol in gynecologic cancer cells

    doi: 10.18632/oncotarget.10921

    Figure Lengend Snippet: a. Western blot analysis of ARID1A protein expression in a panel of 14 endometrial and ovarian cancer cell lines. b. Cell growth of endometrial and ovarian cancer cell lines treated with elesclomol for 72 h as measured using the WST-1 assay. Cell growth was quantified relative to DMSO treated controls. c. IC 50 values of elesclomol in the cell lines in b. d. Apoptosis of ARID1A -mutant and ARID1A -wildtype cells treated with elesclomol for 72 h as measured using annexin-V and PI staining.

    Article Snippet: After transferring the protein to a nitrocellulose membrane, the membrane was incubated with primary antibodies against ARID1A (Sigma-Aldrich), BRG1 (Cell Signaling Technology, Danvers, MA, USA), SNF5 (Cell Signaling Technology), and vinculin (Cell Signaling Technology).

    Techniques: Western Blot, Expressing, WST-1 Assay, Mutagenesis, Staining

    a. Cell growth of ARID1A -wildtype RMG1 and OVCA432 cells transfected with ARID1A and non-target siRNA for 24 h and treated with elesclomol for 72 h. b. Cell growth of RMG1 cells after transfection with BRG1, SNF5, and non-target siRNA and treatment as in a. c. Western blot analysis of RMG1 and OVCA432 cells after transfection with ARID1A, BRG1, SNF5, and non-target siRNA for 48 h. Cell growth was measured using the WST-1 assay and quantified relative to DMSO treated controls. * P < 0.05.

    Journal: Oncotarget

    Article Title: Loss of ARID1A expression leads to sensitivity to ROS-inducing agent elesclomol in gynecologic cancer cells

    doi: 10.18632/oncotarget.10921

    Figure Lengend Snippet: a. Cell growth of ARID1A -wildtype RMG1 and OVCA432 cells transfected with ARID1A and non-target siRNA for 24 h and treated with elesclomol for 72 h. b. Cell growth of RMG1 cells after transfection with BRG1, SNF5, and non-target siRNA and treatment as in a. c. Western blot analysis of RMG1 and OVCA432 cells after transfection with ARID1A, BRG1, SNF5, and non-target siRNA for 48 h. Cell growth was measured using the WST-1 assay and quantified relative to DMSO treated controls. * P < 0.05.

    Article Snippet: After transferring the protein to a nitrocellulose membrane, the membrane was incubated with primary antibodies against ARID1A (Sigma-Aldrich), BRG1 (Cell Signaling Technology, Danvers, MA, USA), SNF5 (Cell Signaling Technology), and vinculin (Cell Signaling Technology).

    Techniques: Transfection, Western Blot, WST-1 Assay

    a. Cell growth of ARID1A -mutant TOV21G cells after transfection with the pCI-neo-ARID1A and pCI-neo control vectors for 48 h and treatment with elesclomol for 72 h. Cell growth was measured using the WST-1 assay and quantified relative to DMSO treated controls. b. Apoptosis of TOV21G cells after transfection and treatment as described in a as measured using annexin-V and PI staining. c. Western blot analysis showing the re-expression of ARID1A in TOV21G cells. * P < 0.05; ** P < 0.01.

    Journal: Oncotarget

    Article Title: Loss of ARID1A expression leads to sensitivity to ROS-inducing agent elesclomol in gynecologic cancer cells

    doi: 10.18632/oncotarget.10921

    Figure Lengend Snippet: a. Cell growth of ARID1A -mutant TOV21G cells after transfection with the pCI-neo-ARID1A and pCI-neo control vectors for 48 h and treatment with elesclomol for 72 h. Cell growth was measured using the WST-1 assay and quantified relative to DMSO treated controls. b. Apoptosis of TOV21G cells after transfection and treatment as described in a as measured using annexin-V and PI staining. c. Western blot analysis showing the re-expression of ARID1A in TOV21G cells. * P < 0.05; ** P < 0.01.

    Article Snippet: After transferring the protein to a nitrocellulose membrane, the membrane was incubated with primary antibodies against ARID1A (Sigma-Aldrich), BRG1 (Cell Signaling Technology, Danvers, MA, USA), SNF5 (Cell Signaling Technology), and vinculin (Cell Signaling Technology).

    Techniques: Mutagenesis, Transfection, WST-1 Assay, Staining, Western Blot, Expressing

    a. Measurement of ROS levels in ARID1A- wildtype RMG1 and OVCA432 cells transfected with ARID1A and non-target siRNA for 72 h using DCFDA. b. Cell growth of RMG1 and OVCA432 cells after transfection with ARID1A and non-target siRNA for 24 h and treatment with the antioxidant NAC for 72 h. Cell growth was measured using the WST-1 assay and quantified relative to DMSO treated non-target control. * P < 0.05; ** P < 0.01; *** P < 0.001.

    Journal: Oncotarget

    Article Title: Loss of ARID1A expression leads to sensitivity to ROS-inducing agent elesclomol in gynecologic cancer cells

    doi: 10.18632/oncotarget.10921

    Figure Lengend Snippet: a. Measurement of ROS levels in ARID1A- wildtype RMG1 and OVCA432 cells transfected with ARID1A and non-target siRNA for 72 h using DCFDA. b. Cell growth of RMG1 and OVCA432 cells after transfection with ARID1A and non-target siRNA for 24 h and treatment with the antioxidant NAC for 72 h. Cell growth was measured using the WST-1 assay and quantified relative to DMSO treated non-target control. * P < 0.05; ** P < 0.01; *** P < 0.001.

    Article Snippet: After transferring the protein to a nitrocellulose membrane, the membrane was incubated with primary antibodies against ARID1A (Sigma-Aldrich), BRG1 (Cell Signaling Technology, Danvers, MA, USA), SNF5 (Cell Signaling Technology), and vinculin (Cell Signaling Technology).

    Techniques: Transfection, WST-1 Assay

    Expression of ARID1A and 8OHdG were determined using immunohistochemistry. Robust nuclear staining of ARID1A was observed for samples 1-4 . Robust cytoplasmic and nuclear staining of 8OHdG was observed for samples 5-8 . Photos were taken at 100×.

    Journal: Oncotarget

    Article Title: Loss of ARID1A expression leads to sensitivity to ROS-inducing agent elesclomol in gynecologic cancer cells

    doi: 10.18632/oncotarget.10921

    Figure Lengend Snippet: Expression of ARID1A and 8OHdG were determined using immunohistochemistry. Robust nuclear staining of ARID1A was observed for samples 1-4 . Robust cytoplasmic and nuclear staining of 8OHdG was observed for samples 5-8 . Photos were taken at 100×.

    Article Snippet: After transferring the protein to a nitrocellulose membrane, the membrane was incubated with primary antibodies against ARID1A (Sigma-Aldrich), BRG1 (Cell Signaling Technology, Danvers, MA, USA), SNF5 (Cell Signaling Technology), and vinculin (Cell Signaling Technology).

    Techniques: Expressing, Immunohistochemistry, Staining

     ARID1A  mutation statuses and  ARID1A  protein expression in a panel of ovarian and endometrial cancer cell lines

    Journal: Oncotarget

    Article Title: Loss of ARID1A expression leads to sensitivity to ROS-inducing agent elesclomol in gynecologic cancer cells

    doi: 10.18632/oncotarget.10921

    Figure Lengend Snippet: ARID1A mutation statuses and ARID1A protein expression in a panel of ovarian and endometrial cancer cell lines

    Article Snippet: After transferring the protein to a nitrocellulose membrane, the membrane was incubated with primary antibodies against ARID1A (Sigma-Aldrich), BRG1 (Cell Signaling Technology, Danvers, MA, USA), SNF5 (Cell Signaling Technology), and vinculin (Cell Signaling Technology).

    Techniques: Mutagenesis, Expressing

    Patient characteristics according to the expression of  BAF250a.

    Journal: Molecular and Clinical Oncology

    Article Title: Effect of ARID1A/BAF250a expression on carcinogenesis and clinicopathological factors in pure-type clear cell adenocarcinoma of the ovary

    doi: 10.3892/mco.2016.973

    Figure Lengend Snippet: Patient characteristics according to the expression of BAF250a.

    Article Snippet: The slides were incubated at 4°C overnight with mouse monoclonal primary antibody against BAF250a (cat. no. sc-32761; dilution, 1:100; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA).

    Techniques: Expressing

    Frequencies of BAF250a-deficient expression in CCA and its precursors. Frequencies of BAF250a-deficient expression were 19% (6/31) in non-atypical EM, 26% (10/38) in atypical EM, 39% (15/38) in EM-related CCA, 1/20 (5%) in benign clear cell adenofibroma (CCAF), 1/21 (5%) in borderline CCAF and 2/21 (10%) in CCAF-related CCA. In solitary EM (control), the frequency of BAF250a-deficient expression was 6% (1/18). BAF250a-deficient expression in EM-related CCA and its precursor was more frequently observed compared with in CCAF-related CCA and its precursor. BAF250a-deficient expression was significantly more frequent in EM-related CCA compared with in CCAF-related CCAF (P=0.015). CCA, clear cell adenocarcinoma; EM, endometrioses; CCAF, clear-cell adenofibroma.

    Journal: Molecular and Clinical Oncology

    Article Title: Effect of ARID1A/BAF250a expression on carcinogenesis and clinicopathological factors in pure-type clear cell adenocarcinoma of the ovary

    doi: 10.3892/mco.2016.973

    Figure Lengend Snippet: Frequencies of BAF250a-deficient expression in CCA and its precursors. Frequencies of BAF250a-deficient expression were 19% (6/31) in non-atypical EM, 26% (10/38) in atypical EM, 39% (15/38) in EM-related CCA, 1/20 (5%) in benign clear cell adenofibroma (CCAF), 1/21 (5%) in borderline CCAF and 2/21 (10%) in CCAF-related CCA. In solitary EM (control), the frequency of BAF250a-deficient expression was 6% (1/18). BAF250a-deficient expression in EM-related CCA and its precursor was more frequently observed compared with in CCAF-related CCA and its precursor. BAF250a-deficient expression was significantly more frequent in EM-related CCA compared with in CCAF-related CCAF (P=0.015). CCA, clear cell adenocarcinoma; EM, endometrioses; CCAF, clear-cell adenofibroma.

    Article Snippet: The slides were incubated at 4°C overnight with mouse monoclonal primary antibody against BAF250a (cat. no. sc-32761; dilution, 1:100; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA).

    Techniques: Expressing, Control

    Tumor response of primary chemotherapy in evaluable cases with ovarian clear cell adenocarcinoma.

    Journal: Molecular and Clinical Oncology

    Article Title: Effect of ARID1A/BAF250a expression on carcinogenesis and clinicopathological factors in pure-type clear cell adenocarcinoma of the ovary

    doi: 10.3892/mco.2016.973

    Figure Lengend Snippet: Tumor response of primary chemotherapy in evaluable cases with ovarian clear cell adenocarcinoma.

    Article Snippet: The slides were incubated at 4°C overnight with mouse monoclonal primary antibody against BAF250a (cat. no. sc-32761; dilution, 1:100; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA).

    Techniques:

    Kaplan-Meier survival curves of all enrolled cases according to the expression status of BAF250a. Progression-free and overall survival curves of BAF250a-deficient expression cases (solid line) and BAF250a-retained cases (dotted line) were produced. (A) The 5-year progression-free survival rate was 59% in BAF250a-deficient expression cases and 68% in BAF150a-retained cases (P=0.24). (B) The 5-year overall survival rate was 49% in BAF250a-deficient expression cases and 67% in BAF150a-retained cases (P=0.43).

    Journal: Molecular and Clinical Oncology

    Article Title: Effect of ARID1A/BAF250a expression on carcinogenesis and clinicopathological factors in pure-type clear cell adenocarcinoma of the ovary

    doi: 10.3892/mco.2016.973

    Figure Lengend Snippet: Kaplan-Meier survival curves of all enrolled cases according to the expression status of BAF250a. Progression-free and overall survival curves of BAF250a-deficient expression cases (solid line) and BAF250a-retained cases (dotted line) were produced. (A) The 5-year progression-free survival rate was 59% in BAF250a-deficient expression cases and 68% in BAF150a-retained cases (P=0.24). (B) The 5-year overall survival rate was 49% in BAF250a-deficient expression cases and 67% in BAF150a-retained cases (P=0.43).

    Article Snippet: The slides were incubated at 4°C overnight with mouse monoclonal primary antibody against BAF250a (cat. no. sc-32761; dilution, 1:100; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA).

    Techniques: Expressing, Produced

    Kaplan-Meier survival curves according to the expression status of BAF250a. (A) Progression-free survival curves of patients with stage I/II disease. The 5-year progression-free survival rate was 91% in BAF250a-deficient cases and 86% in BAF250a-retained expression cases (P=0.82). (B) The overall survival curves of the patients with stage I/II disease were produced. The 5-year overall survival rate was 78% in BAF250a-deficient cases and 85% in BAF250a-retained expression cases (P=0.38). (C) The progression-free survival curves of patients with stage III/IV disease were plotted. The 5-year progression-free survival rate was 13% in BAF250a-deficient cases and 23% in BAF250a-retained cases (P=0.23). (D) The overall survival curves of stage III/IV disease were generated. The solid line indicates BAF250a-deficient cases and dotted line indicates BAF250a-retained cases. The 5-year overall survival rate was 16% in BAF250a-deficient cases and 25% in BAF250a-retained expression cases (P=0.21).

    Journal: Molecular and Clinical Oncology

    Article Title: Effect of ARID1A/BAF250a expression on carcinogenesis and clinicopathological factors in pure-type clear cell adenocarcinoma of the ovary

    doi: 10.3892/mco.2016.973

    Figure Lengend Snippet: Kaplan-Meier survival curves according to the expression status of BAF250a. (A) Progression-free survival curves of patients with stage I/II disease. The 5-year progression-free survival rate was 91% in BAF250a-deficient cases and 86% in BAF250a-retained expression cases (P=0.82). (B) The overall survival curves of the patients with stage I/II disease were produced. The 5-year overall survival rate was 78% in BAF250a-deficient cases and 85% in BAF250a-retained expression cases (P=0.38). (C) The progression-free survival curves of patients with stage III/IV disease were plotted. The 5-year progression-free survival rate was 13% in BAF250a-deficient cases and 23% in BAF250a-retained cases (P=0.23). (D) The overall survival curves of stage III/IV disease were generated. The solid line indicates BAF250a-deficient cases and dotted line indicates BAF250a-retained cases. The 5-year overall survival rate was 16% in BAF250a-deficient cases and 25% in BAF250a-retained expression cases (P=0.21).

    Article Snippet: The slides were incubated at 4°C overnight with mouse monoclonal primary antibody against BAF250a (cat. no. sc-32761; dilution, 1:100; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA).

    Techniques: Expressing, Produced, Generated

    Multivariate analyses for progression-free survival and overall survival.

    Journal: Molecular and Clinical Oncology

    Article Title: Effect of ARID1A/BAF250a expression on carcinogenesis and clinicopathological factors in pure-type clear cell adenocarcinoma of the ovary

    doi: 10.3892/mco.2016.973

    Figure Lengend Snippet: Multivariate analyses for progression-free survival and overall survival.

    Article Snippet: The slides were incubated at 4°C overnight with mouse monoclonal primary antibody against BAF250a (cat. no. sc-32761; dilution, 1:100; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA).

    Techniques: Expressing

    Review of the impact of  BAF250a  on the response to primary chemotherapy and prognoses in ovarian clear cell adenocarcinoma.

    Journal: Molecular and Clinical Oncology

    Article Title: Effect of ARID1A/BAF250a expression on carcinogenesis and clinicopathological factors in pure-type clear cell adenocarcinoma of the ovary

    doi: 10.3892/mco.2016.973

    Figure Lengend Snippet: Review of the impact of BAF250a on the response to primary chemotherapy and prognoses in ovarian clear cell adenocarcinoma.

    Article Snippet: The slides were incubated at 4°C overnight with mouse monoclonal primary antibody against BAF250a (cat. no. sc-32761; dilution, 1:100; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA).

    Techniques: Expressing